Paper Details

  1. Home
  2. Paper Details

A double-masked three-month comparison between 0.25% betaxolol suspension and 0.5% betaxolol ophthalmic solution.

Author: CaldwellD R, GoodeS M, HorwitzB L, LaibovitzR, ShraderC E, StewartR H, WeinrebR N, WilliamsA T

Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

Beta-xolol ophthalmic solution was found to be effective in reducing intraocular pressure in patients with primary open-angle glaucoma or ocular hypertension. However, 0.25% betaxolol suspension was found to be more comfortable for patients to use, as it resulted in significantly less ocular discomfort.
Paper Details　
Original Abstract of the Article :
In 352 patients with primary open-angle glaucoma or ocular hypertension, a multicenter double-masked, parallel-group clinical study compared the effects on intraocular pressure and ocular comfort of 0.5% betaxolol ophthalmic solution, a cardioselective beta-adrenergic blocking agent, with 0.25% beta...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1016/s0002-9394(14)76990-9

データ提供：米国国立医学図書館（NLM）

Navigating the Eye's Desert: A Comparison of Betaxolol Formulations

In the vast landscape of ophthalmology, finding effective and well-tolerated treatments for glaucoma and ocular hypertension is a constant pursuit. This study explores the effects of two different betaxolol formulations - a suspension and a solution - on intraocular pressure and patient comfort. The researchers compared the efficacy and tolerability of these two formulations in patients with glaucoma or ocular hypertension.

Finding the Right Path for Intraocular Pressure Control

The study found that both the 0.25% betaxolol suspension and the 0.5% betaxolol solution effectively reduced intraocular pressure, with no significant difference between the two groups. However, the suspension was found to be significantly better tolerated, resulting in less ocular discomfort upon instillation compared to the solution. This finding suggests that the suspension may be a more comfortable option for patients.

A More Comfortable Journey for Glaucoma Patients

This research highlights the importance of considering patient comfort in addition to efficacy when choosing glaucoma treatments. The study's findings suggest that the betaxolol suspension may be a more comfortable and well-tolerated option for patients, potentially enhancing their overall treatment experience and adherence. This research reminds us to constantly seek ways to improve the comfort and well-being of patients as we navigate the complex landscape of eye care.

Dr. Camel's Conclusion

This study delves into the desert of ophthalmology, highlighting the importance of finding effective and well-tolerated treatments for glaucoma and ocular hypertension. By comparing two different betaxolol formulations, the researchers discovered that the suspension may be a more comfortable option for patients. This research emphasizes the importance of considering patient comfort in addition to efficacy when choosing treatments, ensuring a smoother and more comfortable journey for those navigating the challenges of eye care.

Date :
  1. Date Completed 1990-09-04
  2. Date Revised 2019-06-27
Further Info :

Pubmed ID

2198812

DOI: Digital Object Identifier

10.1016/s0002-9394(14)76990-9

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.